12:00 AM
 | 
Sep 05, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MammaPrint: Phase III data

Agendia N.V., Amsterdam, the Netherlands
Product: MammaPrint
Business: Diagnostic
Molecular target: Not applicable
Description: Breast cancer prognostic test using a 70-gene signature chip
Indication: Predict the risk of metastases in breast cancer patients
Endpoint: Distant metastasis-free survival (DMFS) at 5 years and disease-free survival (DFS); proportion of patients treated with chemotherapy based...

Read the full 249 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >